ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,497Medicare Part D Prescriptions Filled, Including Refills

Rank: 376 out of 1121

$555K Total Retail Price of All Prescriptions

Rank: 340 out of 1121

483 Patients Receiving at Least One Drug in Part D
58%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Tennessee
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

10% of this provider’s 483 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 5,394 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Tennessee
OMEPRAZOLE 432 262 1 6
LISINOPRIL 415 238 2 4
METFORMIN HCL 342 201 3 8
LEVOTHYROXINE SODIUM 325 212 4 2
FUROSEMIDE 305 144 5 7
SIMVASTATIN 249 191 6 1
GABAPENTIN 194 70 7 13
AMLODIPINE BESYLATE 177 126 8 5
HYDROCHLOROTHIAZIDE 173 110 9 10
METOPROLOL TARTRATE 140 99 10 9
MELOXICAM 125 75 11 22
NEXIUM 112 38 12 24
METOPROLOL SUCCINATE 112 85 12 23
METHYLPREDNISOLONE 111 62 14 97
ATORVASTATIN CALCIUM 106 62 15 15
LOVASTATIN 102 55 16 26
TRAMADOL HCL 101 69 17 25
CARVEDILOL 100 67 18 20
WARFARIN SODIUM 97 64 19 11
PREDNISONE 94 60 20 43
HYDROCODONE-ACETAMINOPHEN 93 71 S3 21 3
PRAVASTATIN SODIUM 89 50 22 14
SUCRALFATE 89 43 22 193
CLONIDINE HCL 87 57 24 39
SERTRALINE HCL 86 34 25 21
PROAIR HFA 84 34 26 48
KLOR-CON M20 81 38 27 85
POTASSIUM CHLORIDE 77 30 28 12
DEXILANT 77 24 28 136
LOSARTAN POTASSIUM 75 53 30 17
CEFDINIR 74 38 31 183
ESTRADIOL 74 30 R 31 95
LEVOFLOXACIN 74 52 31 79
ZOLPIDEM TARTRATE 73 42 34 19
AZITHROMYCIN 72 46 35 44
ROPINIROLE HCL 70 38 36 91
RANITIDINE HCL 69 32 37 33
CRESTOR 69 40 37 28
ATENOLOL 67 48 39 16
GLIMEPIRIDE 65 52 40 34
RAMIPRIL 64 28 41 74
PAROXETINE HCL 63 47 42 58
LISINOPRIL-HYDROCHLOROTHIAZIDE 62 50 43 31
SPIRONOLACTONE 60 17 44 54
MECLIZINE HCL 59 34 45 115
CITALOPRAM HBR 55 34 46 18
DONEPEZIL HCL 55 52 46 35
DOXAZOSIN MESYLATE 54 51 48 93
SINGULAIR 54 29 48 78
TAMSULOSIN HCL 54 36 48 32
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 21, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.